Psilocybin + Cognitive Behavioral Therapy for Depression

This trial explores whether adding psilocybin, a compound found in certain mushrooms, to group cognitive-behavioral therapy can help people with major depression. The goal is to determine if this combination effectively reduces depressive symptoms and improves daily life. Participants will take psilocybin in a group setting and attend therapy sessions together. This trial may suit individuals with major depression, active symptoms, and a supportive person to assist with transportation after sessions. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to important early-stage findings.

Yes, you will need to stop taking certain medications. The trial excludes participants currently using antidepressants, other serotonergic substances, lithium, efavirenz, and opioids. However, if you are on anti-hypertensive medications, you must continue taking them.

Research has shown that psilocybin can cause some side effects, but many people tolerate it well. In past studies, psilocybin was linked to negative effects like nausea and increased thoughts of suicide, particularly around the time of dosing. One study found a higher incidence of nausea with psilocybin. However, these effects are not permanent and typically occur shortly after taking the drug.

Despite these side effects, studies have demonstrated that psilocybin can effectively treat depression. Most participants in these studies experienced a significant reduction in depression symptoms. Another study found that these benefits could last up to a year for many patients.

Researchers are excited about psilocybin combined with Cognitive Behavioral Therapy (CBT) for treating depression because it offers a novel approach compared to standard antidepressants like SSRIs and SNRIs. Unlike traditional medications that typically work by altering neurotransmitter levels over weeks, psilocybin acts quickly, often showing effects after just a single dose. Additionally, psilocybin has a unique mechanism of action, activating serotonin receptors in a way that may promote new perspectives and emotional breakthroughs during therapy sessions. This combined approach could provide faster relief and potentially more profound, lasting improvements in depressive symptoms.

Research has shown that psilocybin can help treat major depressive disorder (MDD). Studies have found that psilocybin significantly reduces symptoms of depression, with effects lasting up to a year for many individuals. In one study, a 25 mg dose of psilocybin led to a significant drop in depression severity. Another review of several studies demonstrated that psilocybin improved depressive symptoms much more than a placebo (a fake treatment). Additionally, psilocybin treatment has been linked to increased empathy and self-acceptance, with few side effects reported. Overall, psilocybin appears to be a promising treatment for depression.